

mithra

Women's Health

Mission & Vision

Mithra is a Belgian **biotech company** dedicated to transforming **Women's Health** by offering new choices through innovation, with a focus on contraception and menopause.

Our goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span.


Founders




F. Fornieri

Prof. Dr. JM Foidart

At a Glance



Worldwide Markets



Why invest?

- Breakthrough innovation with the unique hormone **Estetrol (E4)**, **a native estrogen with an improved benefit/risk profile**
- 3 potential blockbusters, including **Estelle®**, a new era in Combined Oral Contraception on the market from 2021, **Donesta®**, the next generation of Hormone Therapy and **PeriNesta®**, the first potential complete oral treatment targeting perimenopause
- **Strong IP Position** with over 35 patent families
- Commercial **partnership strategy** with leaders in women's health
- **Multiple opportunities** beyond women's health
- Worldwide specialist in **long acting drug development** using polymer technology
- **Mithra CDMO**, industry partner with specialist R&D and manufacturing capabilities for polymeric forms, injectables and hormonal tablet products

Corporate strategy


To leverage the full potential of our E4 portfolio, and to develop partnering for our development and manufacturing technology platform.

Portfolio

	Product	Therapeutical area	Phase 1	Phase 2	Phase 3	Market approval
E4	Estelle®	Contraception				2021
	PeriNesta®	Perimenopause				2023
	Donesta®	Menopause				Q4 2023/Q1 2024
	COVID-19 Treatment®	COVID-19				2022
	Under development	CNS, dermatology, etc.	Various stages of non-clinical development of future E4-based pipeline			
			Formulation Clinical/BioEq.	Filing	Market approval	
COMPLEX THERAPEUTICS	Myring™	Contraception	Europe		commercialized	
			U.S.		Q4 2021/Q1 2022	
	Zoreline®	Oncology			2024	
	Tibelia®	Menopause			commercialized	

Share Structure

as of December 31, 2020



Stock Information


as of December 31, 2020

Primary exchange Euronext




Ticker MITRA



Group Structure



Financials



2021 Financial calendar

20-Apr
2020 Annual Report

20-May
Annual General Meeting

24-Sep
2021 Half Year Results

Analyst Coverage

- > **Berenberg**
Beatrice Allen
- > **Degroof Petercam**
Benoît Louage
- > **KBC**
Lenny Van Steenhuyse
- > **Kempen**
Alex Cogut
- > **Kepler Cheuvreux**
Pierre-Alexandre Desir
- > **Portzamparc**
Christophe Dombu



Stay in touch!

Subscribe to our mailing list:

investors.mithra.com/en/contact/#subscribe